DK0764163T3 - Tachykinin (NK1) receptor-antagonister - Google Patents

Tachykinin (NK1) receptor-antagonister

Info

Publication number
DK0764163T3
DK0764163T3 DK95920525T DK95920525T DK0764163T3 DK 0764163 T3 DK0764163 T3 DK 0764163T3 DK 95920525 T DK95920525 T DK 95920525T DK 95920525 T DK95920525 T DK 95920525T DK 0764163 T3 DK0764163 T3 DK 0764163T3
Authority
DK
Denmark
Prior art keywords
compounds
tachykinin
migraine
pain
receptor antagonists
Prior art date
Application number
DK95920525T
Other languages
Danish (da)
English (en)
Inventor
David Christopher Horwell
William Brook Cottage C Howson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0764163T3 publication Critical patent/DK0764163T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
DK95920525T 1994-06-06 1995-05-18 Tachykinin (NK1) receptor-antagonister DK0764163T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25482194A 1994-06-06 1994-06-06
PCT/US1995/006289 WO1995033744A1 (fr) 1994-06-06 1995-05-18 Antagonistes du recepteur de la tachykinine (nk1)

Publications (1)

Publication Number Publication Date
DK0764163T3 true DK0764163T3 (da) 2002-02-04

Family

ID=22965712

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95920525T DK0764163T3 (da) 1994-06-06 1995-05-18 Tachykinin (NK1) receptor-antagonister

Country Status (14)

Country Link
US (1) US5610176A (fr)
EP (1) EP0764163B1 (fr)
JP (1) JPH10501228A (fr)
AT (1) ATE206710T1 (fr)
AU (1) AU693898B2 (fr)
CA (1) CA2187531A1 (fr)
DE (1) DE69523154T2 (fr)
DK (1) DK0764163T3 (fr)
EE (1) EE03445B1 (fr)
ES (1) ES2165915T3 (fr)
NZ (1) NZ287284A (fr)
PT (1) PT764163E (fr)
WO (1) WO1995033744A1 (fr)
ZA (1) ZA954609B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT655055E (pt) * 1992-08-13 2001-03-30 Warner Lambert Co Antagonistas de taquiquinina
CA2189501A1 (fr) * 1995-11-06 1997-05-07 Harry R. Howard Antagonistes des recepteurs de nk-1 pour le traitement du cancer
AU714542B2 (en) * 1996-06-26 2000-01-06 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
US5945508A (en) * 1996-07-23 1999-08-31 Witten; Mark L. Substance P treatment for immunostimulation
EP0935463B1 (fr) * 1996-10-31 2004-01-21 Harbor Branch Oceanographic Institution, Inc. Utilisation de composes et compositions anti-inflammatoires antineurogenes
US6291501B1 (en) 1998-02-20 2001-09-18 Harbor Branch Oceanographic Institution, Inc. Compounds and methods of use for treatment of neurogenic inflammation
JP2002533338A (ja) * 1998-12-18 2002-10-08 ワーナー−ランバート・カンパニー 非ペプチドｎｋ１レセプターアンタゴニスト
ES2218119T3 (es) 1999-02-23 2004-11-16 Ono Pharmaceutical Co., Ltd. Medicamentos cuyos principios activos son derivados de acido fosforico.
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
US6372440B2 (en) 1999-03-10 2002-04-16 Magnesium Diagnostics, Inc. Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
RU2268258C2 (ru) 2000-03-16 2006-01-20 Ф.Хоффманн-Ля Рош Аг Производные карбоновых кислот в качестве антагонистов ip
MY130373A (en) * 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
AU2003243353A1 (en) * 2002-05-29 2003-12-19 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
DK1928427T3 (da) 2005-09-23 2010-03-08 Hoffmann La Roche Hidtil ukendt dosisformulering
EP1940842B1 (fr) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (fr) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (fr) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp)
EP2129381A1 (fr) 2007-01-24 2009-12-09 Glaxo Group Limited Nouvelles compositions pharmaceutiques
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (fr) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibiteurs de l'activité akt
CA2760837C (fr) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et son utilisation
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
WO2010132437A1 (fr) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryle, hétéroaryle et tétrahydroisoquinolines à hétérocycle substitué et leur utilisation
EP2488028B1 (fr) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Pipéridines substituées qui accroissent l'activité de p53 et utilisations de ces composés
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
KR102072631B1 (ko) 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
US20140046059A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Process for the preparation of morpholino sulfonyl indole derivatives
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composés inhibiteurs de erk
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituees en tant qu'inhibiteurs de hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033284A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
JP2022534990A (ja) * 2019-05-30 2022-08-04 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 非感染性免疫炎症性眼障害を処置するための治療アプローチ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
EP0442878A4 (en) * 1988-04-05 1991-10-23 Abbott Laboratories Derivatives of tryptophan as cck antagonists
IE72090B1 (en) * 1991-07-05 1997-03-12 Merck Sharp & Dohme Aromatic compounds pharmaceutical compositions containing them and their use in therapy
US5472978A (en) * 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
JPH06509090A (ja) * 1991-07-10 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む組成物、及び治療におけるそれらの使用
PT655055E (pt) * 1992-08-13 2001-03-30 Warner Lambert Co Antagonistas de taquiquinina

Also Published As

Publication number Publication date
DE69523154D1 (de) 2001-11-15
AU2595095A (en) 1996-01-04
EP0764163B1 (fr) 2001-10-10
WO1995033744A1 (fr) 1995-12-14
ATE206710T1 (de) 2001-10-15
EP0764163A1 (fr) 1997-03-26
EE03445B1 (et) 2001-06-15
PT764163E (pt) 2002-03-28
ES2165915T3 (es) 2002-04-01
JPH10501228A (ja) 1998-02-03
NZ287284A (en) 1998-10-28
CA2187531A1 (fr) 1995-12-14
ZA954609B (en) 1996-01-26
DE69523154T2 (de) 2002-06-06
AU693898B2 (en) 1998-07-09
US5610176A (en) 1997-03-11
EE9600177A (et) 1997-06-16

Similar Documents

Publication Publication Date Title
DE69523154T2 (de) Tachykinin (nk1) rezeptor antagonisten
DE69329712D1 (de) Tachykinin antagonistes
ES2119174T3 (es) Azaciclos espiro-sustituidos como antagonistas de los receptores de las taquiquininas.
MY131442A (en) Excitatory amino acid receptor antagonists
HRP950052B1 (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
DK0737194T3 (da) Diazabicykliske neurokininantagonister
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
MX9805032A (es) Analogos de piperidina 4-sustituida y su uso como antagonistas del receptor de d-asparatato de n-metilo, selectivos para el subtipo.
ATE297755T1 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
DE69703617T2 (de) Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen
EA200500173A1 (ru) Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
DE60003899D1 (de) Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden
EA200300040A1 (ru) 1-аминоалкилциклогексаны в качестве антагонистов 5-нт3 и нейрональных никотиновых рецепторов
EA200300954A1 (ru) Прегабалин-лактозные конъюгаты
ATE402958T1 (de) Antagonisten des ige-rezeptors
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
DE69832302D1 (de) Antikonvulsive und zns-aktive bis-fluoralkylamide
IL147953A0 (en) Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-carboxamide, having anti-epileptic, neurological, and cns activity, and method for their preparation
ATE369354T1 (de) Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems
DE602004008796D1 (de) VERWENDUNG VON 1,3-DIAZADIBENZOÄe,hÜ AZULENEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN FORMULIERUNGEN FÜR DIE BEHANDLUNG UND PRÄVENTION VON ERKRANKUNGEN UND STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS